Phase 1 study of HSK29116, a Bruton tyrosine kinase (BTK) proteolysis-targeting chimera (PROTAC) agent, in patients with relapsed or refractory B-cell malignancies

Authors
Category Primary study
JournalCancer Research
Year 2023
This article has no abstract
Epistemonikos ID: 40f82863ec665b2ef635e9ac5e4efc41dee3ff9b
First added on: Feb 16, 2025